- Azoles
- Polyenes
- Echinocandins
- Allylamines
- Others
Antifungal Drugs Market size was valued at USD 15,623.8 million in 2022 and is expected to grow at a CAGR of 3.9% from 2023 to 2029. The global market provides a detailed overview that can be segmented by drug type, route of administration, Therapeutic indication, and by distribution channel. By drug type, the Antifungal Drugs market growth has been segmented into Azoles, Polyenes, Echinocandins, Allylamines, and Others. The Azoles segment is likely to be the largest and fastest-growing segment in terms of drug type. Azoles are used to treat candidemia, blastomycosis, ocular fungal infections, and systemic candidiasis. It helps in fungistatic activities by hindering fungal enzymes. Azoles are also utilized in the treatment of systemic fungal infections, divided into imidazoles and triazoles. They provide an extensive spectrum of activity along with improved safety levels. Triazoles have less severe effects, fewer serious drug interactions, and enhanced distribution and absorption properties. The above-mentioned advantages of the use of azoles are attributed to the antifungal drug market share. Based on the Route of administration, the Antifungal Drugs market is segmented into Oral, Parenteral, and Topical. Among these, the Topical route of administration segment is expected to have a significantly growing market during the forecast period. Based on the Therapeutic indication, the Antifungal Drugs market is segmented into Aspergillosis, Candidiasis, Dermatophytosis, and Others. The Candidiasis segment is expected to have a significant share in 2021. Candidiasis is the most frequently happening systemic fungal infection. It is a yeast infection by the genus Candida. Its process to cure has changed over time. Some of the variations comprise suitable usage of broad-spectrum azoles and echinocandins for the treatment of candidemia, invasive candidiasis, and mucosal candidiasis. Based on the distribution channel, the Antifungal Drugs market is segmented into Retail pharmacies, Hospital pharmacies, Drug stores, and Online pharmacies.
Antifungal Drugs Market Key Development:
- In June 2021, Mankind Pharma launched Posaconazole Gastro which was a tablet for drug resistance.
- In June 2021, Cadila Pharmaceuticals launched Posaconazole which can be used against an extensive range of fungal disorders.
Global Anti Fungal Drugs Market Summary
Study Period
2023-29
Base Year
2022
CAGR
3.9%
Largest Market
North America
Fastest Growing Market
Europe
Antifungal Drugs Market Dynamics
The growing incidences of nosocomial and fungal infections are anticipated to propel the market growth over the forecast years. Moreover, the growing healthcare expenditure, which helps in refining its infrastructure, is burgeoning the market growth over the forecast years.
North-America Got Significant Share
Anti Fungal Drugs Market Regional Analysis
North America holds the largest share in the antifungal drugs market followed by Europe and Asia-Pacific, owing to increasing patient awareness, R&D expenditure for development of new drugs, and increase in prevalence rate of fungal infections in U.S. (According to Centre for Disease Control and Prevention (CDC) approximately 46,000 new cases of candidiasis occur every year in U.S.) Europe holds a major market share in anti-fungal drugs market attributed to increase in the prevalence rate of fungal infections in Europe and the development of antifungal biopharmaceuticals. Asia Pacific accounts for a significant growth owing to burgeoning consumer base and development in the economies of China and India. Rising income per capita, increasing awareness about the personal hygiene, and increase in healthcare expenditure might fuel the antifungal drugs market in Asia-Pacific region.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Anti Fungal Drugs Market Segmentation
By Drug Class
By Route of Administration
- Oral
- Parenteral
- Topical
By Therapeutic Indication
- Aspergillosis
- Candidiasis
- Dermatophytosis
- Others
By Distribution Channel
- Retail pharmacies
- Hospital pharmacies
- Drug stores
- Online pharmacies
Frequently Asked Questions
The anti-fungal drugs market size was valued at USD 15,623.8 million in 2022
The anti-fungal drugs market key players are: Pfizer, Inc. (U.S.) Novartis AG (Switzerland) Sanofi (France) Merck & Co., Inc. (U.S.) Enzon Pharmaceuticals, Inc. (U.S.) Bayer AG (Germany) Astellas Pharma, Inc. (Japan) GlaxoSmithKline plc. (U.K.) Mylan N.V. (U.S.) Tecan Group (Switzerland) AureoGen Biosciences Inc. (U.S.)
The anti fungal drugs market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1. Executive Summary |
| 2. Global Anti-fungal Drugs Market Introduction |
| 2.1. Global Anti-fungal Drugs Market – Taxonomy |
| 2.2. Global Anti-fungal Drugs Market – Definitions |
| 2.2.1. Drug Class |
| 2.2.2. Route of Administration |
| 2.2.3. Therapeutic Indications |
| 2.2.4. Distribution Channel |
| 3. Global Anti-fungal Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Anti-fungal Drugs Market Dynamic Factors - Impact Analysis |
| 3.6. Global Anti-fungal Drugs Market – Competition Landscape |
| 3.7. Epidemiology |
| 4. Global Anti-fungal Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Anti-fungal Drugs Market, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1. Azoles |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Polyenes |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Echinocandins |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Allylamines |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6. Global Anti-fungal Drugs Market Forecast, By Route of Administration, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Parenteral |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Topical |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Anti-fungal Drugs Market Forecast, By Therapeutic Indications, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1. Aspergillosis |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Candidiasis |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Dermatophytosis |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Others |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8. Global Anti-fungal Drugs Market Forecast (2018 - 2022 and 2023 - 2029) |
| 8.1. Retail Pharmacies |
| 8.1.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Hospital Pharmacies |
| 8.2.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Drug Stores |
| 8.3.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Online Pharmacies |
| 8.4.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 9. Global Anti-fungal Drugs Market Forecast by Region (2018 - 2022 and 2023 - 2029) |
| 9.1. North America |
| 9.1.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn) |
| 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn) |
| 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia-Pacific |
| 9.3.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn) |
| 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Latin America |
| 9.4.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn) |
| 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Middle East and Africa |
| 9.5.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn) |
| 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10. Global Anti-fungal Drugs Market - Opportunity Analysis Index |
| 10.1. By Drug Class, Route of Administration, Therapeutic Indications, Distribution Channel, and Region (2023 - 2029) |
| 11. North America Anti-fungal Drugs Market Analysis (2018 - 2022 and 2023 - 2029) |
| 11.1. Drug Class Analysis |
| 11.1.1. Azoles |
| 11.1.2. Polyenes |
| 11.1.3. Echinocandins |
| 11.1.4. Allylamines |
| 11.1.5. Others |
| 11.2. Route of Administration Analysis |
| 11.2.1. Oral |
| 11.2.2. Parenteral |
| 11.2.3. Topical |
| 11.3. Therapeutic Indications Analysis |
| 11.3.1. Aspergillosis |
| 11.3.2. Candidiasis |
| 11.3.3. Dermatophytosis |
| 11.3.4. Others |
| 11.4. Distribution Channel Analysis |
| 11.4.1. Retail Pharmacies |
| 11.4.2. Hospital Pharmacies |
| 11.4.3. Drug Stores |
| 11.4.4. Online Pharmacies |
| 11.5. Country Analysis |
| 11.5.1. U.S. |
| 11.5.2. Canada |
| 11.6. North America Anti-fungal Drugs Market - Opportunity Analysis Index |
| Continue this format for sections 12, 13, and 14 for Europe, Asia-Pacific, and Latin America, respectively. |
| 12. Europe Anti-fungal Drugs Market Analysis (2018 - 2022 and 2023 - 2029) |
| 12.1. Drug Class Analysis |
| 12.1.1. Azoles |
| 12.1.2. Polyenes |
| 12.1.3. Echinocandins |
| 12.1.4. Allylamines |
| 12.1.5. Others |
| 12.2. Route of Administration Analysis |
| 12.2.1. Oral |
| 12.2.2. Parenteral |
| 12.2.3. Topical |
| 12.3. Therapeutic Indications Analysis |
| 12.3.1. Aspergillosis |
| 12.3.2. Candidiasis |
| 12.3.3. Dermatophytosis |
| 12.3.4. Others |
| 12.4. Distribution Channel Analysis |
| 12.4.1. Retail Pharmacies |
| 12.4.2. Hospital Pharmacies |
| 12.4.3. Drug Stores |
| 12.4.4. Online Pharmacies |
| 12.5. Country Analysis |
| 12.5.1. Germany |
| 12.5.2. UK |
| 12.5.3. France |
| 12.5.4. Spain |
| 12.5.5. Italy |
| 12.5.6. Russia |
| 12.5.7. Poland |
| 12.5.8. Rest of Europe |
| 12.6. Europe Anti-fungal Drugs Market - Opportunity Analysis Index |
| 13. Asia-Pacific Anti-fungal Drugs Market Analysis (2018 - 2022 and 2023 - 2029) |
| 13.1. Drug Class Analysis |
| 13.1.1. Azoles |
| 13.1.2. Polyenes |
| 13.1.3. Echinocandins |
| 13.1.4. Allylamines |
| 13.1.5. Others |
| 13.2. Route of Administration Analysis |
| 13.2.1. Oral |
| 13.2.2. Parenteral |
| 13.2.3. Topical |
| 13.3. Therapeutic Indications Analysis |
| 13.3.1. Aspergillosis |
| 13.3.2. Candidiasis |
| 13.3.3. Dermatophytosis |
| 13.3.4. Others |
| 13.4. Distribution Channel Analysis |
| 13.4.1. Retail Pharmacies |
| 13.4.2. Hospital Pharmacies |
| 13.4.3. Drug Stores |
| 13.4.4. Online Pharmacies |
| 13.5. Country Analysis |
| 13.5.1. Japan |
| 13.5.2. China |
| 13.5.3. India |
| 13.5.4. ASEAN |
| 13.5.5. Australia & New Zealand |
| 13.5.6. Rest of Asia-Pacific |
| 13.6. Asia-Pacific Anti-fungal Drugs Market - Opportunity Analysis Index |
| 14. Latin America Anti-fungal Drugs Market Analysis (2012 - 2018 - 2022 and 2023 - 2029) |
| 14.1. Drug Class Analysis |
| 14.1.1. Azoles |
| 14.1.2. Polyenes |
| 14.1.3. Echinocandins |
| 14.1.4. Allylamines |
| 14.1.5. Others |
| 14.2. Route of Administration Analysis |
| 14.2.1. Oral |
| 14.2.2. Parenteral |
| 14.2.3. Topical |
| 14.3. Therapeutic Indications Analysis |
| 14.3.1. Aspergillosis |
| 14.3.2. Candidiasis |
| 14.3.3. Dermatophytosis |
| 14.3.4. Others |
| 14.4. Distribution Channel Analysis |
| 14.4.1. Retail Pharmacies |
| 14.4.2. Hospital Pharmacies |
| 14.4.3. Drug Stores |
| 14.4.4. Online Pharmacies |
| 14.5. Country Analysis |
| 14.5.1. Brazil |
| 14.5.2. Mexico |
| 14.5.3. Argentina |
| 14.5.4. Venezuela |
| 14.5.5. Rest of Latin America |
| 14.6. Latin America Anti-Fungal Drugs Market - Opportunity Analysis Index |
| 15. Competition Landscape |
| 15.1. Strategic Dashboard of Top Market Players |
| 15.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 15.2.1. Pfizer, Inc. (U.S.) |
| 15.2.2. Novartis AG (Switzerland) |
| 15.2.3. Sanofi (France) |
| 15.2.4. Merck & Co., Inc. (U.S.) |
| 15.2.5. Enzon Pharmaceuticals, Inc. (U.S.) |
| 15.2.6. Bayer AG (Germany) |
| 15.2.7. Astellas Pharma, Inc. (Japan) |
| 15.2.8. GlaxoSmithKline plc. (U.K.) |
| 15.2.9. Mylan N.V. (U.S.), Tecan Group (Switzerland) |
| 15.2.10. AureoGen Biosciences Inc. (U.S.) |
| 16. Research Methodology |
| 17. Key Assumptions and Acronyms |
- Pfizer, Inc. (U.S.)
- Novartis AG (Switzerland)
- Sanofi (France)
- Merck & Co., Inc. (U.S.)
- Enzon Pharmaceuticals, Inc. (U.S.)
- Bayer AG (Germany)
- Astellas Pharma, Inc. (Japan)
- GlaxoSmithKline plc. (U.K.)
- Mylan N.V. (U.S.)
- Tecan Group (Switzerland)
- AureoGen Biosciences Inc. (U.S.)